By Dr. Mercola, August 23, 2021
Monday, August 23, 2021, the U.S. FDA is expected to grant full approval of Pfizer’s mRNA gene therapy for COVID-19 — with one big hitch: Unlike most vaccines they approve, the regulatory body won’t include a public hearing on it before they move the jab from emergency use authorization to full approval.
Ordinarily the Advisory Commission on Immunization Practices (ACIP) and Vaccines and Related Biological Products Advisory Committee (VRBPAC) hold meetings with public input before a final full approve is given for a vaccine.
But in this instance, an FDA spokesperson told The BMJ that those meetings aren’t necessary because all three COVID-19 jabs — Pfizer’s, Moderna’s and Johnson & Johnson’s — had public input at the December 20, 2020, VRBPAC meeting.
As reported by The BMJ, “Kim Witczak, a drug safety advocate who serves as a consumer representative on the FDA’s Psychopharmacologic Drugs Advisory Committee, said the decision removed an important mechanism for scrutinizing the data.
“’These public meetings are imperative in building trust and confidence especially when the vaccines came to market at lightning speed under emergency use authorization,’” she said. “’The public deserves a transparent process, especially as the call for boosters and mandates are rapidly increasing. These meetings offer a platform where questions can be raised, problems tackled, and data scrutinized in advance of an approval.’”
SOURCE: The BMJ August 20, 2021